EMD Serono, Inc. Announces Appointment of James Hoyes as President

  • James Hoyes to lead US operations of Merck KGaA, Darmstadt, Germany pharmaceutical business

ROCKLAND, Mass.--(BUSINESS WIRE)-- EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, announced today that James Hoyes has been appointed President of EMD Serono. In this capacity, he will be responsible for driving the strategic direction of the US commercial organization as well as managing the day-to-day business of the US affiliate of Merck KGaA. Mr. Hoyes will also serve as a member of the Executive Management Board for Merck Serono, the global pharmaceuticals division of Merck KGaA.

“Jim’s experience, leadership and vision will add significant value to our US operations,” said Dr. Stefan Oschmann, Member of the Executive Board of Merck KGaA and President of Merck Serono. “He has a strong knowledge of the industry and expertise across a variety of commercial functions, including sales, marketing, communications, managed markets, and collaborations. We are confident that Jim will enhance the reputation of EMD Serono as a leader in biopharmaceuticals in the US.”

Mr. Hoyes previously served as Chief Commercial Officer for EMD Serono, responsible for business operations in the company’s key therapeutic areas of neurodegenerative diseases, rheumatology, fertility and metabolic endocrinology, as well as managed care, business intelligence, health outcomes, specialty pharmacy and commercial operations.

"I look forward to working with our leadership teams and our employees in continuing to provide patients with important treatments and services, to delivering successful business outcomes, and to driving medical advancements through research and development,” says Mr. Hoyes. “The people of EMD Serono are incredibly talented and passionate about our purpose of making a difference in society and in the lives of patients, and I am proud to be a part of this team.”

Mr. Hoyes also led the neurology franchise at EMD Serono, managing the operations of sales, marketing, communications, call center operations, and medical affairs. He joined EMD Serono in February 2004 as Vice President of Marketing in neurology.

Prior to joining EMD Serono, Mr. Hoyes gained experience in a variety of commercial roles of increasing responsibilities at Elan, Sanofi and Sterling Drug. Mr. Hoyes also has extensive experience working in a partnership environment (such as co-promotion and joint venture agreements) with other biopharmaceutical companies such as Pfizer, BMS, UCB and Wyeth.

Mr. Hoyes graduated from the Pennsylvania State University with a Bachelor of Science in Biology.

About EMD Serono, Inc.

EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, is a leader in the US biopharmaceutical arena, integrating cutting-edge science with unparalleled patient support systems to improve people's lives. The company has strong market positions in neurodegenerative diseases, with Rebif® (interferon beta-1a), as well as in endocrinology, with Saizen® (somatropin (rDNA origin) for injection), Serostim® (somatropin (rDNA origin) for injection) and EGRIFTA® (tesamorelin for injection). EMD Serono is a leader in reproductive health, with Gonal-f® (follitropin alfa for injection), Luveris® (lutropin alfa for injection) and Ovidrel® Prefilled Syringe (choriogonadotropin alfa injection). In addition, EMD Serono is growing its expertise and presence in the area of oncology, with more than 10 projects currently in development. With a clear focus on the patient and a leadership presence in the biopharmaceutical industry, EMD Serono’s US footprint continues to grow, with more than 1100 employees around the country and fully integrated commercial, clinical and research operations in the company’s home state of Massachusetts.

For more information, please visit www.emdserono.com

About Merck KGaA

Merck is a global pharmaceutical and chemical company with total revenues of € 9.3 billion in 2010, a history that began in 1668, and a future shaped by more than 40,000 employees in 67 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.

For more information, please visit www.merckserono.com or www.merck.de


EMD Serono, Inc.
Heather Connor, 781-681-2124

KEYWORDS:   United States  Europe  North America  Massachusetts  Germany

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Other Science  Science  General Health